Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Med Chem ; 33(11): 2963-70, 1990 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-2146392

RESUMEN

Spirogermanium (1; 8,8-diethyl-N,N-dimethyl-2-aza-8- germaspiro[4.5]decane-2-propanamine dihydrochloride) is a potent cytotoxic agent in vitro which has demonstrated limited activity in experimental animal tumor models. Subsequently, it has been reported that spirogermanium has antiarthritic and suppressor cell-inducing activity. We have synthesized a series of substituted 8-hetero-2-azaspiro[4.5]decane and 9-hetero-3-azaspiro[5.5]undecane analogues of spirogermanium to identify the heteroatom requirements for in vivo antiarthritic and suppressor cell-inducing activity. This structure-activity relationship study has identified that appropriately substituted silicon and carbon analogues of spirogermanium retain both antiarthritic and immunosuppressive activity, with the 8,8-dipropyl (carbon) analogue being among the most active. Following the identification of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride (9) as a more active analogue than spirogermanium, a series of 8,8-dipropyl analogues with various amine substituents were synthesized. A number of these analogues had activity similar to that of 9. A correlation between activity in the adjuvant arthritic rat and the ability to induce suppressor cells (r = 0.894, p less than 0.001) suggests an association between the two pharmacologic effects. While the precise biochemical mechanism(s) for the pharmacological activity is unclear, these data suggest that compounds within this series, e.g., N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride, may provide effective therapy in diseases of autoimmune origin and/or the prevention of rejection in tissue transplantation.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Compuestos Aza/farmacología , Inmunosupresores/farmacología , Compuestos de Espiro/farmacología , Linfocitos T Reguladores/efectos de los fármacos , Animales , Compuestos Aza/síntesis química , Compuestos Aza/uso terapéutico , Fenómenos Químicos , Química , Inmunosupresores/síntesis química , Inmunosupresores/uso terapéutico , Masculino , Estructura Molecular , Compuestos Organometálicos/farmacología , Compuestos Organometálicos/uso terapéutico , Ratas , Ratas Endogámicas Lew , Compuestos de Espiro/síntesis química , Compuestos de Espiro/uso terapéutico , Relación Estructura-Actividad , Linfocitos T Reguladores/inmunología
2.
Anticancer Drug Des ; 3(4): 231-42, 1989 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2930625

RESUMEN

Spirogermanium is a germanium containing azaspirane which has been shown to have activity in experimental models of cancer and immune dysfunction. A series of analogs of the parent compound were synthesized and evaluated in a number of in vitro and in vivo biological assays to define the structure-activity relationships of this class of compounds relative to their potential therapeutic activities. In a colony-forming assay using HT-29 human colon carcinoma cells various analogs in which carbon replaced germanium (e.g. carbon) retained the potent cytotoxic activity in vitro seen with spirogermanium. Increased cytotoxic potency within the group of carbon containing analogs was directly related to increase in the length of the alkyl group(s) attached to the carbon atom opposite the azaspirane ring structure. DNA and protein synthesis by HT-29 cells was inhibited by these compounds. However, inhibition occurred only at supralethal concentrations or after long exposure times with the drug. None of the azaspiranes demonstrated in vivo anti-tumor activity against P388 leukemia or ADJ-PC6 plasmacytoma. The effect of these compounds on macrophage cell function was evaluated in vitro by their ability to modulate superoxide (O2-) production by macrophages. Spirogermanium inhibited the production of O2- by activated macrophages with an IC50 of 5 microM. Although macrophage viability did not appear to be decreased at the respective IC50 concentrations, the rank order potency for the analogs in the O2- production assay was directly proportional to that measured for their cytotoxic potency in the HT-29 colony formation assay. The results demonstrate that, within this class of compounds, (1) potent biological activity does not require the presence of germanium in the structure; (2) in vitro cytotoxic activity does not appear to be a direct result of the inhibition of macromolecular synthesis, and (3) macrophage function can be modulated in vitro at non-cytotoxic concentrations. These results are discussed in context with the reported anti-tumor activity of spirogermanium and the potential anti-arthritic and immunomodulatory activity of this class of compounds.


Asunto(s)
Antineoplásicos , Macrófagos/efectos de los fármacos , Compuestos Organometálicos/farmacología , Compuestos de Espiro/farmacología , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Antineoplásicos/toxicidad , Carcinoma/tratamiento farmacológico , Neoplasias del Colon/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Leucemia P388/tratamiento farmacológico , Activación de Macrófagos/efectos de los fármacos , Macrófagos/fisiología , Masculino , Ratones , Ratones Endogámicos , Compuestos Organometálicos/uso terapéutico , Compuestos Organometálicos/toxicidad , Plasmacitoma/tratamiento farmacológico , Compuestos de Espiro/uso terapéutico , Compuestos de Espiro/toxicidad , Relación Estructura-Actividad , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA